Status:
RECRUITING
18F-sodium Fluoride (NaF) PET to Replace Bone Scintigraphy: Safety and Efficacy Assessment
Lead Sponsor:
Centre de recherche du Centre hospitalier universitaire de Sherbrooke
Collaborating Sponsors:
Université de Sherbrooke
Conditions:
Bone Cancer
Articular Disease
Eligibility:
All Genders
Phase:
PHASE3
Brief Summary
18F-sodium fluoride (18F-NaF) was already investigated numerous times in the last 40 years as a PET alternative to standard 99m-technetium-derived bone scintigraphy. However, lack of universal tracer ...
Eligibility Criteria
Inclusion
- Patients for whom a 99mTc-biphosphonate bone scintigraphy is indicated;
- Pediatric patients for whom a 99mTc-biphosphonate bone scintigraphy is indicated for oncologic or infectious reasons
- Able to tolerate supine position
- Written consent
Exclusion
- Healthy subjects
- Pregnancy
- Unable of maintaining supine position for more than 15 minutes
- Refusal to sign the consent form
- Known allergy or hypersensitivity to 18F-NaF or any of its constituants.
Key Trial Info
Start Date :
January 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
2500 Patients enrolled
Trial Details
Trial ID
NCT04842071
Start Date
January 1 2008
End Date
December 31 2025
Last Update
February 7 2024
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
CHUS
Sherbrooke, Quebec, Canada, J1H 5N4
2
Université deSherbrooke
Sherbrooke, Quebec, Canada, J1H5N4